LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | Selumetinib | 10.0 | uM | LJP6 | 1 | M07 | 72 | hr | 513 | 1065 | 10401 | 0.1024 | 0.0558 |
| MCF 10A | Selumetinib | 10.0 | uM | LJP6 | 2 | M07 | 72 | hr | 513 | 763 | 10401 | 0.0734 | 0.0252 |
| MCF 10A | Selumetinib | 10.0 | uM | LJP6 | 3 | M07 | 72 | hr | 513 | 873 | 10401 | 0.0839 | 0.0364 |
| MCF 10A | Sirolimus | 10.0 | uM | LJP6 | 1 | L13 | 72 | hr | 513 | 10694 | 10401 | 1.0282 | 1.0296 |
| MCF 10A | Sirolimus | 10.0 | uM | LJP6 | 2 | L13 | 72 | hr | 513 | 9467 | 10401 | 0.9102 | 0.9055 |
| MCF 10A | Sirolimus | 10.0 | uM | LJP6 | 3 | L13 | 72 | hr | 513 | 9659 | 10401 | 0.9287 | 0.9249 |
| MCF 10A | Sorafenib | 10.0 | uM | LJP6 | 1 | B07 | 72 | hr | 513 | 5938 | 10401 | 0.5709 | 0.5486 |
| MCF 10A | Sorafenib | 10.0 | uM | LJP6 | 2 | B07 | 72 | hr | 513 | 5958 | 10401 | 0.5728 | 0.5506 |
| MCF 10A | Sorafenib | 10.0 | uM | LJP6 | 3 | B07 | 72 | hr | 513 | 5970 | 10401 | 0.5740 | 0.5519 |
| MCF 10A | SU11274 | 10.0 | uM | LJP5 | 1 | J07 | 72 | hr | 513 | 2723 | 10401 | 0.2618 | 0.2235 |
| MCF 10A | SU11274 | 10.0 | uM | LJP5 | 2 | J07 | 72 | hr | 513 | 2592 | 10401 | 0.2492 | 0.2102 |
| MCF 10A | SU11274 | 10.0 | uM | LJP5 | 3 | J07 | 72 | hr | 513 | 2491 | 10401 | 0.2395 | 0.2000 |
| MCF 10A | Fedratinib | 10.0 | uM | LJP5 | 1 | L01 | 72 | hr | 513 | 530 | 10401 | 0.0510 | 0.0017 |
| MCF 10A | Fedratinib | 10.0 | uM | LJP5 | 2 | L01 | 72 | hr | 513 | 578 | 10401 | 0.0556 | 0.0065 |
| MCF 10A | Fedratinib | 10.0 | uM | LJP5 | 3 | L01 | 72 | hr | 513 | 604 | 10401 | 0.0581 | 0.0092 |
| MCF 10A | TGX221 | 10.0 | uM | LJP5 | 1 | H19 | 72 | hr | 513 | 6975 | 10401 | 0.6706 | 0.6535 |
| MCF 10A | TGX221 | 10.0 | uM | LJP5 | 2 | H19 | 72 | hr | 513 | 7601 | 10401 | 0.7308 | 0.7168 |
| MCF 10A | TGX221 | 10.0 | uM | LJP5 | 3 | H19 | 72 | hr | 513 | 8447 | 10401 | 0.8121 | 0.8024 |
| MCF 10A | Torin1 | 10.0 | uM | LJP6 | 1 | O13 | 72 | hr | 513 | 997 | 10401 | 0.0959 | 0.0489 |
| MCF 10A | Torin1 | 10.0 | uM | LJP6 | 2 | O13 | 72 | hr | 513 | 987 | 10401 | 0.0949 | 0.0479 |
| MCF 10A | Torin1 | 10.0 | uM | LJP6 | 3 | O13 | 72 | hr | 513 | 607 | 10401 | 0.0584 | 0.0095 |
| MCF 10A | Torin2 | 10.0 | uM | LJP5 | 1 | I19 | 72 | hr | 513 | 470 | 10401 | 0.0452 | -0.0044 |
| MCF 10A | Torin2 | 10.0 | uM | LJP5 | 2 | I19 | 72 | hr | 513 | 478 | 10401 | 0.0460 | -0.0036 |
| MCF 10A | Torin2 | 10.0 | uM | LJP5 | 3 | I19 | 72 | hr | 513 | 504 | 10401 | 0.0485 | -0.0009 |
| MCF 10A | Tozasertib | 10.0 | uM | LJP5 | 1 | B13 | 72 | hr | 513 | 740 | 10401 | 0.0711 | 0.0229 |